• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Adagene Inc ADR (NQ: ADAG )

    2.510 -0.060 (-2.33%)
    Streaming Delayed Price Updated: 3:02 PM EDT, Jul 19, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 7,363
    Open 2.550
    Bid (Size) 2.510 (1)
    Ask (Size) 2.590 (1)
    Prev. Close 2.570
    Today's Range 2.500 - 2.610
    52wk Range 1.100 - 4.380
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September
    From Adagene Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga

    Performance

    YTD
    +28.07%
    +28.07%
    1 Month
    -19.03%
    -19.03%
    3 Month
    -4.92%
    -4.92%
    6 Month
    -4.92%
    -4.92%
    1 Year
    +88.73%
    +88.73%

    More News

    Read More
    Adagene to Present at Investor Conferences in June
    From Adagene Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    How Is The Market Feeling About Adagene?
    Via Benzinga
    Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
    From Adagene Inc.
    Via GlobeNewswire
    Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
    From Adagene Inc.
    Via GlobeNewswire
    Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
    From Adagene Inc.
    Via GlobeNewswire
    Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic
    From Adagene Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Week in Review: Lee’s Pharma Signs $138 Million Agreement For China Rights To Heart Failure Therapy
    Via Talk Markets
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Why Is Cancer Focused Adagene Stock Plummeting Today?
    Via Benzinga
    Why DatChat Shares Are Trading Lower By Around 33%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Via InvestorPlace
    Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
    From Adagene Inc.
    Via GlobeNewswire
    Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium
    From Adagene Inc.
    Via GlobeNewswire
    Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
    From Adagene Inc.
    Via GlobeNewswire
    Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
    From Adagene Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.